Disease-free survival in patients with stage III resected colon cancer is not improved by adding cetuximab to mFOLFOX6 (the modified sixth version of the standard adjuvant therapy [leucovorin, fluorouracil and oxaliplatin]). In this randomized trial, the 3-year disease-free survival for mFOLFOX6 compared with mFOLFOX6 plus cetuximab was 74.6% versus 71.5% for patients with wild-type KRAS and 67.1% versus 65.0% for those with mutated KRAS. Adverse events (grade 3 or higher) were also significantly higher with cetuximab.
ORIGINAL RESEARCH PAPER
Alberts, S. R. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. JAMA doi:10.1001/jama.2012.385
Rights and permissions
About this article
Cite this article
Adding cetuximab to mFOLFOX6 does not improve disease-free survival in patients with stage III resected colon cancer. Nat Rev Gastroenterol Hepatol 9, 302 (2012). https://doi.org/10.1038/nrgastro.2012.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.83
